Department of Chemical Engineering & Biotechnology, Institute of Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK.
Expert Rev Proteomics. 2012;9(1):97-108. doi: 10.1586/epr.11.70.
Schizophrenia is a debilitating mental disorder that affects approximately 30 million people worldwide. The development and progression of this disease is now thought to be precipitated through a complex interaction between altered gene function and environmental factors. Proteomic analyses have been applied extensively over the past 10 years in studies of several tissues from schizophrenic patients, resulting in increased insight into the affected molecular pathways. In addition, these proteomic approaches have led to the identification of a set of molecular biomarker assays as the first blood-based test to aid in the diagnosis of schizophrenia. Here, we discuss the main outcome of these investigations and suggest a practical means of integrating and translating the findings between the brain and peripheral blood to increase our understanding of schizophrenia pathophysiology.
精神分裂症是一种使人虚弱的精神疾病，全球约有 3000 万人受其影响。目前认为，这种疾病的发展和进展是由基因功能改变和环境因素之间的复杂相互作用引发的。在过去的 10 年中，蛋白质组学分析已广泛应用于精神分裂症患者的几种组织研究中，这使得人们对受影响的分子途径有了更多的了解。此外，这些蛋白质组学方法还鉴定出了一组分子生物标志物检测，作为首个有助于诊断精神分裂症的基于血液的检测。在这里，我们讨论了这些研究的主要结果，并提出了一种实用的方法，将大脑和外周血之间的研究结果进行整合和转化，以增进我们对精神分裂症病理生理学的理解。
